Elicio Therapeutics, Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference

Yeah, of course. Great place to start. Elicio Therapeutics is a clinical-stage cancer immunotherapy company. We're focused on immunotherapies that are directed specifically to the lymph nodes. We believe that the lymph nodes are a key site in our body which orchestrate the immune response against cancer. To date, it's been a challenge to get these immunotherapies to the cells that matter in the lymph nodes. You can see here we're doing that with a platform approach, which we call Amphiphile or AMP. This is a technology developed at Massachusetts Institute of Technology intended to direct immunotherapy specifically to lymph nodes and the immune cells that reside there. We have proof of concept from 2 completed phase I trials and a randomized phase II, which had a final analysis earlier this summer. We can talk certainly about that.

The lead candidate is our ELI-002, which is a KRAS specific immunotherapy designed to target the seven most common mutant forms of KRAS. We have some exciting data from the randomized phase II trial, as well as from a series of patients that were on that trial that then went on to receive subsequent therapy, including a checkpoint- that had some notable radiographic responses in the metastatic setting.

So, excited to talk more about that.

Yeah, there are two things that I would point to. The first one is just the technology has improved dramatically. Historically, cancer vaccines, especially the types that we work on, have had significant challenges in getting to the places where they can have their biological effect, the lymph nodes. There was a decade's worth of research done at MIT to study that, and then to develop this Amphiphile approach for lymph node targeted immunotherapy. What that does is get these agents directly to the immune cells, which then orchestrate the immune response against cancer. There is a potency challenge that needed to be overcome. The other thing that has been a challenge is the setting of disease.

We started out studying minimal residual disease, and we are now moving our way into metastatic disease. One of the things that has come alongside of that is checkpoint inhibition.

This is a tool that with the synergistic effect with a cancer vaccine, could become a very potent combination for future therapy in cancer.

Yeah. These are two very exciting readouts, and I think we can learn quite a bit from them. Firstly, melanoma is not CRC. I think on the spectrum of cancers that are thought to be sensitive to immunotherapy, melanoma is certainly at the far end, a place where you have abundant neoantigens, where the standard of care does involve immunotherapy already. So adding a vaccine to that checkpoint backbone therapy seems like a really good idea, and I think the data speaks for itself. The CRC setting is a little bit more challenging, perhaps a little bit more refractory to immunotherapy. The backbone standard therapy does not involve immunotherapy, so you're sort of building onto a foundation that does not yet exist.